208 related articles for article (PubMed ID: 30531358)
1. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder.
Vieta E; Earley WR; Burgess MV; Durgam S; Chen C; Zhong Y; Barabássy Á; Németh G
Int Clin Psychopharmacol; 2019 Mar; 34(2):76-83. PubMed ID: 30531358
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
[TBL] [Abstract][Full Text] [Related]
4. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Fava M; Durgam S; Earley W; Lu K; Hayes R; Laszlovszky I; Németh G
Int Clin Psychopharmacol; 2018 Nov; 33(6):312-321. PubMed ID: 30045066
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
[TBL] [Abstract][Full Text] [Related]
8. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Sachs GS; Yeung PP; Rekeda L; Khan A; Adams JL; Fava M
Am J Psychiatry; 2023 Mar; 180(3):241-251. PubMed ID: 36789515
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
[TBL] [Abstract][Full Text] [Related]
13. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Riesenberg R; Yeung PP; Rekeda L; Sachs GS; Kerolous M; Fava M
J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37585254
[No Abstract] [Full Text] [Related]
14. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive cariprazine as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis.
Xie M; Qiu Y; Wang M; Wei X; Tao Y; Duan A; Shang J; Gao W; Wang Z
J Psychiatr Res; 2024 Apr; 172():71-80. PubMed ID: 38367320
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
Lepola U; Hefting N; Zhang D; Hobart M
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
